ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Rhea-AI Summary

ORIC (NASDAQ: ORIC) reported 2025 operational highlights and 2026 milestones, emphasizing clinical progress for rinzimetostat (ORIC-944) in mCRPC and enozertinib in NSCLC. Key clinical metrics: rinzimetostat showed PSA50 in 55% (confirmed 40%), PSA90 in 20%, and ctDNA >50% reduction in 76% with 59% clearance. Enozertinib showed strong systemic activity (1L ORR 67% in EGFR exon 20; 80% in EGFR PACC) and 100% intracranial ORR in measurable CNS disease. Company selected provisional RP2Ds, plans a Phase 3 start for rinzimetostat in 1H 2026, and expects multiple 2026 readouts. Financials: raised $244M in 2025; cash and investments of $413M expected to fund operations into 2H 2028.

Positive

• Raised $244M in 2025 from private placement and ATM
• Cash and investments of $413M expected to fund operations into 2H 2028
• Rinzimetostat: PSA50 55% and ctDNA >50% reduction 76% in mCRPC dose exploration
• Enozertinib: 1L systemic ORR 67% (EGFR exon 20) and 80% ORR (EGFR PACC); 100% intracranial ORR in measurable CNS disease

Negative

• Raised capital via private placement and ATM, implying equity issuance that may dilute existing shareholders
• All programs remain in clinical development with no registrational approvals yet; key value realization depends on upcoming 2026 readouts

News Market Reaction

%

35 alerts

% News Effect

+7.5% Peak in 2 hr 44 min

$1.01B Market Cap

1.3x Rel. Volume

On the day this news was published, ORIC declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.5% during that session. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Capital raised 2025: $244 million Cash & investments: $413.0 million PSA50 response rate: 55% (11/20 patients) +5 more

8 metrics

Capital raised 2025 $244 million Gross proceeds from healthcare specialist funds via private placement and ATM

Cash & investments $413.0 million As of September 30, 2025; expected runway into 2H 2028

PSA50 response rate 55% (11/20 patients) Rinzimetostat Phase 1b in mCRPC, PSA50 responses across dose levels

PSA90 response rate 20% (4/20 patients) Rinzimetostat Phase 1b in mCRPC, confirmed PSA90 responses

ctDNA reduction 76% (13/17 patients) Rinzimetostat Phase 1b, >50% ctDNA reduction across AR mutations

ctDNA clearance 59% (10/17 patients) Rinzimetostat Phase 1b, ctDNA clearance vs precedent standard-of-care trials

1L ORR EGFR exon 20 67% ORR Enozertinib Phase 1b in 1L NSCLC with EGFR exon 20 mutations

1L ORR EGFR PACC 80% ORR; 100% intracranial ORR Enozertinib Phase 1b in 1L NSCLC with EGFR PACC mutations

Market Reality Check

Price: $12.12 Vol: Volume 1,556,654 is 8% ab...

normal vol

$12.12 Last Close

Volume Volume 1,556,654 is 8% above the 20-day average of 1,441,092. normal

Technical Price $9.15 is trading below the 200-day MA at $9.50.

Peers on Argus

ORIC gained 8.28% while peers were mixed: NUVB -4.29%, MAZE +3.52%, RAPP +1.26%,...

ORIC gained 8.28% while peers were mixed: NUVB -4.29%, MAZE +3.52%, RAPP +1.26%, ATNF +2.92%, ELVN +10.26%, indicating a stock-specific move rather than a uniform sector trend.

Common Catalyst One peer, NUVB, also had J.P. Morgan Healthcare Conference-related news on the same day, but this did not produce a consistent sector-wide price direction.

Historical Context

5 past events · Latest: Jan 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	Conference appearance	Neutral	-0.1%	Announced CEO presentation at 44th Annual J.P. Morgan Healthcare Conference.
Dec 05	Clinical data update	Positive	-4.4%	Reported strong enozertinib Phase 1b EGFR exon 20 NSCLC efficacy and CNS data.
Dec 05	Equity grants	Neutral	-4.4%	Disclosed inducement stock options and RSUs for new non-executive employees.
Dec 05	Clinical data update	Positive	-3.5%	Presented enozertinib data in HER2 exon 20 NSCLC with solid ORR and safety.
Dec 04	Clinical data update	Positive	+3.8%	Showed strong systemic and CNS activity for enozertinib in EGFR atypical NSCLC.

Pattern Detected

Recent clinically positive updates for enozertinib often saw mixed or negative next-day moves, suggesting past news flow did not always translate into immediate price strength.

Recent Company History

Over the past months, ORIC has focused on advancing enozertinib and rinzimetostat through multiple Phase 1b presentations and corporate updates. December 2025 featured several data releases at the ESMO Asia Congress, highlighting strong systemic and intracranial activity in EGFR atypical and HER2 exon 20 NSCLC, along with inducement equity grants. An early January 2026 notice confirmed ORIC’s appearance at the 44th Annual J.P. Morgan Healthcare Conference. Today’s operational update builds directly on those clinical and corporate milestones.

Market Pulse Summary

This announcement details robust Phase 1b results for both rinzimetostat and enozertinib, alongside ...

Analysis

This announcement details robust Phase 1b results for both rinzimetostat and enozertinib, alongside $413.0 million in cash and investments expected to fund operations into 2H 2028. It highlights strong PSA and ctDNA responses in mCRPC and high systemic and intracranial ORRs in EGFR exon 20 and PACC NSCLC. Historically, ORIC has regularly shared detailed trial updates and conference presentations. Investors may watch 2026 dose-optimization data, planned Phase 3 initiations, and further readouts as key validation milestones.

Key Terms

mcrpc, psa50, psa90, ctdna, +3 more

7 terms

mcrpc medical

"efficacy and safety in mCRPC; selected provisional RP2Ds and initiated"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

psa50 medical

"with 55% of patients (11/20) achieving a PSA50 response (confirmed in 40%)"

A PSA50 is a clinical measure meaning a 50% or greater drop in the level of prostate‑specific antigen (PSA), a blood protein used to track prostate cancer activity. Investors watch PSA50 because it is an early, easy-to-measure sign that a treatment may be working; stronger or more frequent PSA50 responses in trials can boost confidence in a drug’s effectiveness, influence regulatory outlook and affect a company’s valuation.

psa90 medical

"and 20% of patients (4/20) achieving a PSA90 response (all confirmed)"

PSA90 denotes a 90% or greater drop in prostate-specific antigen (PSA) levels from a patient’s starting value, used as a shorthand measure of how strongly a prostate cancer treatment is reducing tumor activity. For investors, PSA90 is a quick signal of a drug’s efficacy in clinical trials—like seeing a thermometer fall sharply after treatment—and can influence regulatory expectations, market value, and licensing potential.

ctdna medical

"Rapid and deep ctDNA responses across a breadth of AR mutations"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

nsclc medical

"activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

egfr exon 20 medical

"NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3"

EGFR exon 20 is a specific part of a gene that helps control cell growth. Changes or mutations in this area can lead to uncontrolled cell division, which is a common feature in certain types of lung cancer. Understanding these mutations helps doctors decide the best treatment options for patients.

atm (at-the-market) program financial

"funds via private placement in May 2025 and under the ATM (at-the-market) program"

An at-the-market (ATM) program lets a company sell newly issued shares directly into the open market at the current trading price, essentially drip-feeding stock to raise cash as needed. Investors care because it provides a flexible way for a company to get funding without a big one-time offering, but it can increase the number of shares outstanding and put downward pressure on the stock price if used extensively.

AI-generated analysis. Not financial advice.

Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors

Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose

Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study

Expect to report multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential initiation of multiple registrational trials

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced operational highlights for 2025 and anticipated upcoming milestones.

“2025 was a transformative and highly productive year for ORIC, marked by meaningful progress across our pipeline, including data that further strengthened our conviction in the potential best-in-class profiles of rinzimetostat in prostate cancer and enozertinib in lung cancer,” said Jacob M. Chacko, M.D., president and chief executive officer. “We also bolstered our leadership team and substantially extended our cash runway into 2H 2028 in anticipation of these programs advancing towards registrational studies and, ultimately, commercialization.”

2025 Key Accomplishments

Rinzimetostat: a potent and selective allosteric inhibitor of PRC2

• Completed Phase 1b dose exploration in prostate cancer and selected provisional recommended Phase 2 doses (RP2Ds) of rinzimetostat to be tested in combination with the approved doses of darolutamide and apalutamide in dose optimization.
• Reported potential best-in-class efficacy and safety dose exploration data in combination with darolutamide and apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Data demonstrated:
  • PSA responses and ctDNA reductions across all rinzimetostat dose levels and at comparable rates in combination with apalutamide or with darolutamide.
  • Broad and deep PSA responses that compare favorably to competitor PRC2 inhibitors, with 55% of patients (11/20) achieving a PSA50 response (confirmed in 40%), and 20% of patients (4/20) achieving a PSA90 response (all confirmed).
  • Rapid and deep ctDNA responses across a breadth of AR mutations and other gene alterations, with 76% (13/17) achieving > 50% ctDNA reduction, and 59% (10/17) achieving ctDNA clearance, which is greater than clearance rates observed in precedent trials with standard of care agents in comparable mCRPC patient populations.
  • Both combination regimens demonstrated a clearly differentiated safety profile compatible with long-term dosing, with the vast majority of treatment-related adverse events (TRAEs) Grade 1 or 2 in severity and consistent with PRC2 and AR inhibition.
• Presented preclinical data at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics demonstrating potential utility of rinzimetostat combined with AR inhibition in castration-sensitive prostate cancer and combined with KRAS inhibition in KRAS G12C-mutant NSCLC and colorectal cancer models.
  
  

Enozertinib: a brain-penetrant inhibitor that selectively targets EGFR exon 20 and EGFR PACC mutations

• Reported potential best-in-class efficacy and safety data from a Phase 1b trial of enozertinib at the ESMO Asia Congress 2025 in NSCLC patients with EGFR exon 20 and EGFR PACC mutations. Data demonstrated:
  • Systemic activity in 2L EGFR exon 20 and pretreated EGFR PACC exceeding competitor benchmarks.
  • Highly competitive preliminary 1L systemic activity, with 67% ORR in EGFR exon 20 and 80% ORR in EGFR PACC.
  • Convincing 1L CNS activity, with 100% intracranial ORR in EGFR exon 20 and 100% intracranial ORR in EGFR PACC in patients with measurable CNS disease, including in patients with active brain metastases.
  • Competitive safety profile, with no significant off-target toxicity, resulting in low rate of treatment discontinuations.
• Announced a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab) for the 1L treatment of NSCLC patients with EGFR exon 20 mutations.
• Announced publication in Cancer Research of preclinical data demonstrating enozertinib’s exquisite selectivity, strong potency, brain-penetrance, and anti-tumor activity across a broad range of EGFR atypical mutant models, including intracranial lung cancer xenografts.
  
  

Corporate Highlights:

• Announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO).
• Strengthened cash position and extended runway with $244 million in gross proceeds raised from new and existing top-tier healthcare specialist funds via private placement in May 2025 and under the ATM (at-the-market) program throughout 2025.
  
  

Anticipated Program Milestones:

ORIC anticipates the following upcoming milestones:

• Rinzimetostat in mCRPC:
  • 1Q 2026: Combination dose optimization data with AR inhibitor
  • 1H 2026: Initiate first global Phase 3 registrational trial in mCRPC
  • 2H 2026: Program update
• Enozertinib in NSCLC:
  • 2H 2026: 1L EGFR exon 20 monotherapy data and combination data with SC amivantamab
  • 2H 2026: 1L EGFR PACC monotherapy data
    
    

Financial Guidance
As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond several potential value inflection points, including anticipated primary endpoint readout from first Phase 3 trial of rinzimetostat.

Presentation and Webcast
Jacob M. Chacko, M.D., president and chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2025, at 9:45 a.m. PT. A live webcast will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 and atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat (ORIC-944) and enozertinib; the potential advantages of rinzimetostat and enozertinib; clinical outcomes, which may materially change as patient enrollment continues or more patient data become available; statements regarding the potential best-in-class properties of rinzimetostat and enozertinib; the development plans and timelines for rinzimetostat and enozertinib; plans underlying ORIC’s clinical trials and development; anticipated program milestones, including timing of program and data updates and the initiation of registrational trials; the period over which ORIC estimates its existing cash, cash equivalents and investments will be sufficient to fund its current operating plan; and statements by the company’s chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on November 13, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What clinical results did ORIC (ORIC) report for rinzimetostat in mCRPC in 2025?

Rinzimetostat dose exploration showed PSA50 in 55% (40% confirmed), PSA90 in 20%, and 76% of evaluable patients had >50% ctDNA reduction with 59% ctDNA clearance.

When does ORIC expect to start the Phase 3 registrational trial for rinzimetostat (ORIC-944)?

The company anticipates initiating the first global Phase 3 registrational trial for rinzimetostat in 1H 2026.

What efficacy did enozertinib (ORIC) show in 1L NSCLC with EGFR exon 20 and PACC mutations?

Enozertinib reported preliminary 1L systemic ORR of 67% in EGFR exon 20 and 80% in EGFR PACC, plus 100% intracranial ORR in patients with measurable CNS disease.

How much cash does ORIC (ORIC) have and how long is the runway?

As of September 30, 2025, ORIC had $413.0M in cash, cash equivalents and investments, expected to fund operations into 2H 2028.

What upcoming ORIC (ORIC) clinical readouts are expected in 2026?

ORIC expects multiple 2026 readouts including rinzimetostat combination dose optimization in 1Q 2026, and enozertinib 1L monotherapy and combination data in 2H 2026.

Did ORIC (ORIC) select doses for future trials of rinzimetostat?

Yes, ORIC selected provisional RP2Ds for rinzimetostat to be tested in combination with approved doses of darolutamide and apalutamide.